TrialNature medicine2023

Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.

Nabil F Saba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.